About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7739 record(s)
Req # A-2019-001598
Adverse Reaction Report (AER) for NINLARO. Report number: E2B_02747790.Organization: Health Canada
March 2020
Req # A-2019-001602
Adverse Reaction Report (AER) for PANTOPRAZOLE. Report numbers: 000728933, 000729469, E2B_02721101, E2B_02726898, E2B_02727599, E2B_02733268, E2B_02738003, E2B_02742861, E2B_02743130, E2B_02745655, E2B_02747521, E2B_02747529, E2B_02751738, E2B_02751804, E2B_02751741, E2B_02754906, E2B_02754923, E2B_02757724, E2B_02757731, E2B_02757767, E2B_02758901.Organization: Health Canada
March 2020
Req # A-2019-001612
Adverse Reaction Report (AER) for CEFIXIME. Report numbers: E2B_02555912, E2B_02432931.Organization: Health Canada
March 2020
Req # A-2019-001616
Adverse Reaction Report (AER) for CODEINE SULFATE. Report number: E2B_02200066.Organization: Health Canada
March 2020
Req # A-2019-001617
Adverse Reaction Report (AER) for leflunomide. Report number: E2B_02456998.Organization: Health Canada
March 2020
Req # A-2019-001619
Adverse Reaction Report (AER) for Cipralex® (escitalopram). Report numbers: E2B_02535962, E2B_02543869, 000726867, 000726987, 000727052, E2B_02585107 and E2B_02610804 AER for Celexa® (citalopram). Report numbers: 000724951, E2B_02528143, E2B_02531324, E2B_02545002, E2B_02546282, 000730190, E2B_02560599, E2B_02585524 E2B_02593006, 000727666, E2B_02633993, E2B_02637017 AER for Ebixa® (memantine). Report number: E2B_02591899 AER for Clopixol® (zuclopenthixol). Report numbers: 000726118, 000727766 AER for Trintellix® (vortioxetine). Report number: 0000726365.Organization: Health Canada
March 2020
Req # A-2019-001732
Adverse Reaction Report (AER) for DEXILANT. Report numbers: E2B_02792258, E2B_02799100.Organization: Health Canada
March 2020
Req # A-2019-001647
Adverse Reaction Report (AER) for HYDROCODONE TARTRATE, PHENYLEPHRINE HYDROCHLORIDE. Report number: E2B_02144626.Organization: Health Canada
March 2020
Req # A-2019-001648
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02228615, E2B_02386796, E2B_02092633.Organization: Health Canada
March 2020
Req # A-2019-001657
Adverse Reaction Report (AER) for SODIUM AUROTHIOMALATE. Report numbers: E2B_02112424, E2B_02120344, E2B_02123701, E2B_02230814, E2B_02074075, E2B_02098052, E2B_02104850, E2B_01804139, E2B_02273808, E2B_02266431, E2B_02192705, E2B_02355882.Organization: Health Canada
March 2020